

Eastwood Bio-Medical Canada Inc. (EBM)

July 15, 2020



1130-4871 Shell Road, Richmond, BC, Canada
V6X 3Z6



Forward-Looking Statement

This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Eastwood Bio-Medical Canada Inc. (the Company) and the Company's affiliates, including expectations and assumptions concerning TSX Venture Exchange approvals. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Disclaimer

Although the data found in this Investor Deck have been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, legality, reliability or usefulness of any information. This disclaimer applies to both isolated and aggregate uses of the information. The information is provided on an "as is" basis.

Changes may be periodically made to the information herein; these changes may or may not be incorporated in any new versions of this Investor Deck. It is recommended that careful attention be paid to the contents of any information associated with a file, and that the originator of the data or information be contacted with any questions regarding appropriate use. If you find any errors or omissions, please report them to info@eastwoodcos.com.

Notwithstanding claims or statements made by any officer, director, employee, related party, or affiliate of Eastwood Bio-medical Canada in any form including written or verbal, EBM makes no claims regarding any products it distributes or manufactures except for the sanctioned claims referred to in slide 4 of this Investor Deck. Readers should consider only these claims when evaluating this document.

Disclaimer

Except for the claims allowed by Health Canada Product Licenses 80000196, 80000364, 80000365, 80000477, 80000481, 80000504, 80000866, the Singapore Health Science Authority CDA (HSU) 40:43/01-B(V), the National Pharmaceutical Administration NPA (CPM) 6:06 /1 Vol 19, the Food and Drug Administration Authority (Republic of China) 0900027995, the Food and Drug Administration Authority (Peoples Republic of China) Import Food Hygiene Supervision and Inspection Bureau Certificate 990067, the Food and Drug Administration Authority Approval Number J20060001, neither Eastwood Bio-Medical Canada Inc., its affiliated companies, its employees, its distributors, nor its personnel make any claims that the products distributed by Eastwood Bio-medical Canada cure, diagnose, or prevent any diseases.

Disclaimer

Eastwood Bio-medical Canada Inc. (EBM) is not liable for any information provided on this Investor Deck with regard to recommendations regarding the mentioned products for any health purposes. The products or claims made about specific nutrients or products have not been evaluated by the United States Food and Drug Administration. Dietary products are not intended to treat, prevent or cure disease. Consult with a healthcare professional before starting any diet, supplement or exercise program. EBM makes no guarantee or warranty with respect to any products or services sold. EBM is not responsible for any damages for information provided by the Investor Deck even if EBM has been advised of the possibility of damages. Statements regarding potential health benefits from taking EBM products that appear on this website have not been evaluated by the FDA, and may not have been evaluated by any other governmental body.



Eastwood Bio-Medical Canada Inc. is located at Richmond, British Columbia, Canada near the Vancouver International Airport.

Canadian History in Diabetes Leadership

Canada has long been considered the global pioneer of the diabetes industry. In 1922, Frederick Grant Banting discovered insulin, which is considered one of the most important discoveries of the 20th century. The Nobel Foundation awarded his team the Nobel Prize in Physiology and Medicine in 1923.



Who We Are

A company specializing in metabolic disorders such as diabetes, obesity, hypertension, and Alzheimer's disease.

We have successfully developed over 70 Eleotin® products including over 60 Health Canada (Canadian FDA) approved products.

Advertising Standards Canada (ASC) approved our flagship product, Eleotin® Bentley to be marketed as “**World's #1** Doctor recommended Natural Source Healthy Blood Glucose Promoting Product available in Canada”.



9

Who We Are

As of 2018, over 500,000 users are estimated to have used and benefited from Eleotin®. (An estimated 200,000 users as of 2014, or as of the ASC approval stamp)

More than four international health associations strongly recommend (endorsed) Eleotin®.

Eleotin® was the recipient of Best Diabetic & Hypertension Management Drug of the Year 2010*, and

7th Annual International Brand Packaging Gold Award.

*Institute for Government Research & Leadership Technology, Nigeria
Please see Disclaimers on slides 3, 4, and 5.

EBM: The Recent Focus of Financial Analysts and Investors

Company production capacity 'recently' has increased to:

- Up to 3 million capsules can be produced and 10,000 bottles can be packaged per day.
- A half million dollar worth of products in retail value can be produced daily.
- Up to \$7 million in possible savings in annual manufacturing costs.



EBM: The Recent Focus of Financial Analysts and Investors



EBM: The Recent Focus of Financial Analysts and Investors

New Product Approvals and Licenses (Over 100 NPN Numbers).



June 29 2018, Eastwood Bio-Medical Canada Enters Binding Terms for Asian Exports

- On June 29 2018, EBM announced entering binding terms for Asian exports. The Company is optimistic that this will result in an increase in revenues.
- New manufacturing capabilities allow the Company to finally start producing highly advanced and complex products with the best quality and process control on a meaningfully larger scale.
- The facilities and operations meet Good Manufacturing Practices standards, and retain site licenses from Health Canada and a foreign government.
- EBM is no longer being bound by production limitations.

Stock Draws International Attention



HOME TRY OUR FREE RESEARCH TOOL AAPL GOOG FB MSFT GE JNJ TSLA ABOUT



EBM'S INVESTMENT
OVERVIEW

Eastwood Bio-Medical Canada



We're Excited To See How Eastwood Bio-Medical Canada (CVE:EBM) Uses Its Cash Hoard To Grow

Simply Wall St March 2, 2020

Just because a business does not make any money, does not mean that the stock will go down.

For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.

Given this risk, we thought we'd take a look at whether **Eastwood Bio-Medical Canada** ([CVE:EBM](#)) shareholders should be worried about its cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. Let's start with an examination of the business's cash, relative to its cash burn.

Stock Draws International Attention

Forget Marijuana: These 2 Unknown Canadian Stocks Have Returned up to 6,570% in 2018

Brian Paradza, CFA | December 18, 2018 | More on:

EBM

POG

Stock Draws International Attention

MARKETS

TSXV Biggest Percentage Gainers
Mid-Afternoon: Eastwood Bio
Medical, Senator Minerals, Ultra
Lithium

CONTRIBUTOR


MT Newswires — [MTNewswires](#)

PUBLISHED

APR 18, 2016 2:37AM EDT




Market Potential: Prevalence of Diabetes By IDF Region




Market Potential: Prevalence of Alzheimer's and Dementia

Alzheimer's and dementia patients worldwide



Market Potential: Prevalence of Hypertension

Global Prevalence of Hypertension over 1.3 Billion



Market Values of Diabetes, Hypertension and Alzheimer's

- Type 2 diabetes market to more than double, to **\$64 billion** by **2026**
- Global hypertension market will reach USD **\$32 billion** by the end of **2020**
- The global Alzheimer's market is expected to **\$10.4 billion** in **2021**

1. GlobalData's report: PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2026
2. Technavio
3. GBI Research - Alzheimer's Disease Therapeutics Market to 2021

Our Claim: The Only Option

We believe that our products are the ‘only’ natural sourced option for those inflicted with these diseases.

We also believe we will remain the only option in the near future.

Here is why...

Please see Disclaimers on slides 3, 4, and 5.

Advantage #1: Modes of Action Known

Pharmaceutical Drugs and Insulin	Other Herbal Products	Traditional Chinese Medicine	Folkloric Treatments/ Alternative Treatments	Eleotin®
Known - Can be used with other pharmaceutical drugs	Unknown	Unknown	Unknown	Known - Can be safely used with other pharmaceutical drugs

- The Modes of Actions for most non-pharmaceutical treatments are unproven. They can not be used with pharmaceutical drugs out of fear of unknown adverse interactions.
- Eleotin®'s modes of actions are known and proven. Eleotin® is safe when used with oral pharmaceutical drugs and insulin.
- In fact, Eleotin® reduces the side effects and resistance of oral pharmaceutical drugs and insulin. When used with Eleotin®, oral pharmaceutical drugs and insulin become safer, more efficacious, and less habit forming.

Please see Disclaimers on slides 3, 4, and 5.

Advantage #2: Long Term Effects

Pharmaceutical Drugs and Insulin	Other Herbal Products	Traditional Chinese Medicine	Folkloric Treatments/ Alternative Treatments	Eleotin®
None	None	Unknown	None	Semi-permanent efficacy

- With proven insulin resistance reduction, Eleotin® provides semi-permanent long term improvement while other treatments do not give such long term benefits.
- Most other treatments only have short term control benefits, and must be used permanently.
- But a person can stop Eleotin® with no harmful side effects after the body has attained structural change.

For more information, please contact info@eastwoodcos.com
Please see Disclaimers on slides 3, 4, and 5.

Advantage #3: Preventive Effects

Pharmaceutical Drugs and Insulin	Other Herbal Products	Traditional Chinese Medicine	Folkloric Treatments/ Alternative Treatments	Eleotin®
No	No	No	No	Yes

- A person who does not have diabetes can use Eleotin® for general health and preventive purposes. Other treatments do not offer such safe options.

Conclusion

Pharmaceutical Drugs and Insulin	Other Herbal Products	Traditional Chinese Medicine	Folkloric Treatments/ Alternative Treatments	Eleotin®
Short term and invasive treatment. Toxic and severe side effects. Resistance develops. Ever increasing dosages.	Shotgun approach. Most of them rely on artificial indigestion to lower the blood sugar.	Shotgun approach. Most of them rely on artificial indigestion to lower the blood sugar.	Shotgun approach. Most of them rely on artificial indigestion to lower the blood sugar.	Long term and safe beneficial effects. General health improvements.

- If you compare Eleotin® with other treatments from all perspectives, it's natural to conclude that Eleotin® is the only natural sourced option.

As a Result,

Advertising Standards Canada (ASC) approved Eleotin® to be marketed as “**World’s #1** Doctor recommended Natural Source Healthy Blood Glucose Promoting Product available in Canada”.

- World’s No.1 Doctor recommended: Over 3000+ doctors
- Over 2,500 Newspaper & Television Acclaims (including New York Times #1 Best Sellers)
- Researched/Clinically tested by Universities and Governments
- Strongly recommended by more than 4 Associations
- Licenses issued by 8 Government Authorities
- Best Diabetic & Hypertension Management Drug of the Year 2010*
- As of 2018, more than 500,000 Users, and over 2,000 Youtube testimonials


*Institute for Government Research & Leadership Technology, Nigeria
Please see Disclaimers on slides 3, 4, and 5.

Trends Favourable For Eleotin® Products (1)

The deadly side effects of common pharmaceutical drugs for metabolic disorders are being reported and published with increasing frequency.

THE WALL STREET JOURNAL.

[BUSINESS](#) | [HEALTH CARE](#) | [HEALTH](#)



FDA Says Up to Two Million People Exposed to Likely Carcinogens in Blood-Pressure Drugs

[BUSINESS](#) | [HEALTH CARE](#) | [HEALTH](#)



FDA Asks Five Companies to Recall Diabetes Drug Metformin

Trends Favourable For Eleotin® Products (2)

Accordingly, Eleotin®'s unique position as the world's # 1 scientific supported natural and safe health promoter for metabolic disorder will become more widely accepted. Eastwood believes Eleotin® products will eventually replace most of pharmaceutical drugs for metabolic disorders on the market place.

30

Recommendations of Medical Professionals



Dr. Chu, Beijing China
“Because of Eleotin my husband doesn’t need any pharmaceutical drugs. He’s normal now.”



Dr. L. Lipskaya, Bacteriologist
“After I started using Eleotin, I felt an improvement in my health conditions. Now I recommend Eleotin to every person who are suffering from Type II diabetes.”



Dr. P. Singh
Ayurvedic Medicine
“I want to recommend Eleotin especially to Type II diabetics. It will help them in controlling their blood glucose levels.”



Dr. C. L. Broadhurst
“Eleotin is blend of many promising herbs that dramatically lower blood sugar.”



Dr. D. Walker
“Eleotin is effective in regulating blood glucose levels. ”



Dr. M. Sichel
“A pathfinding discovery in the reversal of diabetes.”



Dr. E. Echano
“Everyone should know about this. I observed excellent clinical result. This unique herbal formulations long lasting effects are truly amazing.”

These are unsolicited third party opinions from unaffiliated individuals based on their own independent research. Except for claims referred to on slides 3, 4, and 5, EBM takes no responsibility for any claims.

Please see Disclaimers on slides 3, 4, and 5.

[illegible][illegible][illegible][illegible][illegible]

Nutrition and Foods Safety Agency of the Centre for Disease
Prevention and Control, People's Republic of China

	Page 4 of 4
Name of Sample:	Electron
Source received from:	Bentley International Enterprise Co., Ltd Taiwan Free Trade Zone
Manufacturer:	Japan's National Medical Research Inc.
Sample Number:	200804
Expiration Date:	25 months from manufacturing date no color change noted under inspection
Sample Description:	Type: capsule Color: contents light brown powder
Amount of Sample Received:	0.3g capsule x 30 capsules/bottle x 1 bottle = 9.0g capsule x 30 capsules/bottle
Sample Received on:	May 1 st , 2008
Sample Used for:	Sample submitted as a supplement to decreasing blood glucose level (animal testing) and for Health Food Products Testing (EBC)
Testing Reference:	Decreasing Blood Glucose: 2003
Testing Results:	The results of the test that Electron had no effect on the blood glucose levels of the normal subject (laboratory mice) after fasting (overnight + 0.5%). Compared with the control group, the blood glucose levels of the group that received the blood glucose levels (p=0.05 or 0.01) after fasting (overnight meal with previously consumed food) were significantly lower than the control group (p=0.05 or 0.01). After 48 hours (fasting, medium dose, and low dose). After oral feeding of glucose to all Electron dose groups, the blood glucose levels of these groups were still significantly lower than the control group (p=0.05 or 0.01). According to the standards set by National Health Products Testing and Evaluation Center (2003), the feeding of Electron had no effect on blood glucose levels. supplementing the decrease of blood glucose level in an animal experiment.

[illegible]

卫生部认定保健食品检验机构

卫生部卫监发(1996年)第53号

University of Calgary
(UTI) officials



Press conference at the
launching of the first Eleotin

Clinical Studies, Publications, Approvals, and Licenses

SUCCESS IS JUST THAT SIMPLE

The Analysis Results of 300 Diabetics Cases

ELEOTIN has been on the market in North America for 8 years, and hundreds of thousands diabetics are no longer suffering from diabetes because of it. In China, ELEOTIN has become well known, especially in neutralizing and adjusting/preventing complications from diabetes. ELEOTIN has shown great effectiveness.

To have a better understanding of ELEOTIN, we have done a detailed analysis by evaluating 300 diabetics. The 300 diabetics vary from ages 23 to 87. The period of time these patients took ELEOTIN varies from a short period of 1 month to a longer period of 8 months. Among these 300 cases, 256 were Type 2 diabetes (non-insulin dependent) and 44 were type 1 (insulin dependent).

Among the 256 patients with Type 2 diabetes, the blood glucose level (BGL) control and complications were different. Some of these patients had just recently been diagnosed, and others already had diabetes for decades. For these patients, some BGL were high during fasting, some were high 2 hours after meals, and some of them were high in both. Diabetics who were diagnosed for more than 5 years had one or more complications. In their clinical findings, symptoms of numbness and pain in the limbs and joints, fatigue, insomnia, skin itchiness, weak vision were present.

By taking ELEOTIN, 70% of these patients had stabilized their blood glucose level and 98% of their complications had improved. Some of them even had reduced dosage of pharmaceutical medications prescribed by physicians.

The following chart helps better explain the advantages of ELEOTIN:

1. This chart shows the percentage of people, Time taking ELEOTIN, and those with Reduced or Stopped Medication

Time on ELEOTIN	Number of Persons	People with Reduced/Stopped Medications	Percentage of People
Over 6 Months	96	62	64.6%
4 ~ 6 Months	142	59	41.5%
2 ~ 3 Months	40	5	12.5%
1 Months	22		

2. This chart shows the difference of symptoms and the BGL after taking ELEOTIN

BGL & Symptoms before taking ELEOTIN	Number of Persons	BGL & Symptoms improved after taking ELEOTIN	Better Transitions
High BGL	224	187	83.5%
BGL under control	32	32	100%
Insulin dependent	44	39	86.6%
Numbness on limb	56	47	83.9%
Fatigue	65	48	73.8%
Itchy skin	30	22	73%
Insomnia	34	25	73.5%
Weak vision	38	16	42.1%
Sweating	26	15	57.7%
Thirst	43	28	65.1%
Active urination at night	49	27	55.1%
Red swollen feet	3	2	66.7%
Impotence	7	6	85.7%

The above statistics are from an extensive analysis of the 300 diabetes cases. We are grateful to see the dramatic effectiveness of ELEOTIN according to the numbers shown with those who gain from the benefits. ELEOTIN will show its unique and powerful results to nourish and repair if given the time and patience. By decreasing or stopping intake of ELEOTIN before fully investing the time and effort, more than 70% of diabetics will maintain their BGL in normal or close to normalcy without bouncing back.

Such powerful result is due in fact by its ability to alleviate insulin whose basic function is to control the amount of glucose in the blood. In doing so, ELEOTIN helps the establishment and repairing of B cells and increase in production of insulin. It can also balance the chemical reaction of insulin and beta cells and reduce the insulin resistance. By that the body will increase the metabolism of glucose.

Please see Disclaimers on slides 3, 4, and 5.

Clinical Studies, Publications, Approvals, and Licenses

약업신문

1998년 10월 8일 목요일

Executive

캐나다에 거주하는 교포의 화자가 참여하고 교포가 운영하는 회사들이 공동으로 획기적인 당뇨병 치료제를 개발한 것으로 알려져 주목되고 있다.

최근 캐나다의 한 교포회사인 EBMR(Eastwood Bio-Medical Research Inc.)사가 발표한 바에 따르면 이번이 개발된 약물은 700여 차례의 임상실험을 실시한 결과 발병 6개월 이내의 성인형 당뇨병을 70% 이상 치료한 것으로 밝혀졌다.

P-700이라는 이 약물은 또 각종 천연약초에서 추출된 생약물질로 되어 있어 부작용과 내성이 전혀 없다고 EBMR 측은 발표했다.

EBMR은 이 약물이 해당조절뿐 아니라 인슐린을 생산하는 췌장 베타세포의 기능을 감

화하고 근육조직에서 인슐린을 잡아주는 수용체를 다시 살아나게 해 당뇨병을 근본적으로 치료해 준다고 설명했다.

이번 당뇨병 치료제는 캐나다 캘거리대학교 당뇨병연구센터가 기초연구 및 동물실험등을 실시했고 제정하는 EBMR측에서 추진하고 있는 것으로 전

ty Technologies International이라는 회사를 통해 EBMR과 상품개발 계약이 체결됐다.

이번 신약개발에 일조한 윤박사는 23년간 바이러스와 관련된 당뇨병의 원인과 예방에 대한 연구로 매우 높은 평가를 받고 있는 것으로 전해졌다.

EBMR측은 "윤박사가 노벨 의학상에 두 번이나 후보 추천된 인물임은 정

加교포 획기적 당뇨병 치료제 개발

윤지원박사, 700여차례 임상 80% 완치

해지고 있다.

이 약물개발에는 특히 캐나다 캘거리대학교에 재직하고 있는 교포 윤지원박사(아주대 의대 교수)가 많은 기여를 한 것으로 알려져 있으나 윤박사는 '공동 연구한 것'이라는 입장을 보이고 있다.

이번에 개발된 [P-700]은 캘거리대학교의 산·학공조단체인 UTI(Universi-

ty Technologies International이라는 회사를 통해 EBMR과 상품개발 계약이 체결됐다.

이번 신약개발에 일조한 윤박사는 23년간 바이러스와 관련된 당뇨병의 원인과 예방에 대한 연구로 매우 높은 평가를 받고 있는 것으로 전해졌다.

EBMR측은 "윤박사가 노벨 의학상에 두 번이나 후보 추천된 인물임은 정

도로 당뇨병 분야의 세계적 권위자"라고 소개했다.

윤박사는 EBMR은 요령, 열려 커뮤니케이션 장비제조, 금융투자, 국제무역등의 관련업무를 하고 있는 이스트우드(Eastwood)의 계열사이며, 의학 관련 벤처기업으로 캐나다에 거주하는 한국인 교포 김영수(42)씨가 운영하는 회사이다.

(민경두기자)

Comments on Eleotin®
by the Korean National
Diabetes Association

Clinical Studies, Publications, Approvals, and Licenses



새 "당뇨병치료물질" 개발

"천연약초서 추출...부작용 전혀 없어"

EBMR산등 공동발표

캐나다 갈가리대 외대 당뇨연구센터와 개발 파트너인 EBMR사는 천연약초에서 새로운 당뇨병 치료물질을 개발하는 데 성공했다고 공동 발표했다.

이에 앞서 EBMR사는 이미 'P-700'을 이용한 건강차 '엘레오틴'을 지난 4월부터 북미지역에서 판매하기 시작했으며, 당뇨병치료 의약품 개발을 추진중이다.

공동개발자인 EBMR사는 캐나다 밴쿠버 소재의 교포기업인 이스트우드사(김영수 사장)와 제휴사로 당뇨병과 암치료제를 전문적으로 개발중인 신약개발 전문회사다.

'P-700'으로 명명된 이 당뇨병 치료물질은 천연약초에서 추출돼 기존 당뇨병 치료제에 비해 부작용이나 내성이 전혀 없는 것으로 나타났다고 갈가리대학과 EBMR사는 밝혔다.

EBMR사는 "임상실험 결과 'P-700'은 혈당을 조절하는 기존 당뇨병치료제 기능외에도 인슐린을 생산하는 췌장의 베타세포 기능을 강화하고, 근육 조직에서 인슐린을 잡아채는 수용체를 재생하는 효능까지 있다"고 밝혔다.

EBMR사는 "성인병의 대명사로 난치병으로 알려진 당뇨병을 치료할 수 있는 길을 보여준 셈"이라고 설명했다. 하지만 이런 신약이 개발돼 당뇨병자에게 보급되기까지 걸리는 기간은 대략 7~10년이 걸린다고 한다.

약사공론 1998. 10. 8 제 3081 호

당뇨치료제 개발 캐나다 훈지원박사

캐나다에 거주하는 교포과학자에 의해 당뇨 치료에 획기적인 신약이 개발돼 화제가 되고 있다.

캐나다 앨버타 대학의 공식 발표에 따르면 앨버타대학교 당뇨연구센터 훈지원 박사가 만류어년 'P-700'이라는 단세포 이미 700여 차례의 임상실험을 통해 발현된 지 5개월 이내의 실험형 당뇨병에 비해서는 70% 이상 혈당수치를 낮추며 발동수입을 증진시켜 획기적인 효과를 거두고 있는 것으로 나타났다.

이번 당뇨병 신약은 밴쿠버의 EBMR사와 앨버타대학 당뇨연구센터가 산학연계를 통해 공동연구를 추진한 성과로 신약의 상용화에 대한 권리는 EBMR사가 갖기로 계약했으며 이미 엘레오틴이라는 이름의 건강차로 출시되어 북미지역에

판매가 진행되고 있는 것으로 확인되었다.

훈지원박사(53)는 지난 22년간 바이러스와 관련된 당뇨병과 췌장과 배당에 대한 연구로 이미 세계 일인자로 꼽히는 인물로 올년 KDS 해외종교상학부문상을 수상한 바 있다.

Comments by Eleotin® by the Korean Pharmaceutical Manufacturers' Association

Africa's Best Diabetic & Hypertension Management Drug in 2010*



INSTITUTE FOR GOVERNMENT RESEARCH & LEADERSHIP TECHNOLOGY
Office of the Country Director/CEO (Africa & Middle East)

The Managing Director/CEO
Eleotin GP Ltd
Goodnews Plaza, Suite A6
4B, Agbaoku Street, Opebi, Ikeja
Lagos State, South West Nigeria

Monday October 4 2010

Dear Sir,

BEST DIABETIC & HYPERTENSION MANAGEMENT DRUG OF THE YEAR 2010

In the spirit of Nigeria's 50th Independence celebration, Institute for Government Research & Leadership Technology have the honour to make this award in favour of ELEOTIN GP LTD having out performed other companies in the production of fine Diabetic pharmaceuticals in Nigeria.

- 2) Some of the parameters and performance indices used are:
- Your compliance with Government regulatory laws and guidelines;
 - your prowess and contribution in the production of drugs;
 - product's high quality and value creation;
 - Corporate Marketing strategy;
 - Product's price and pricing strategy;
 - Product's acceptability, satisfaction and endorsement;
 - corporate general performance and track record;
 - product's unique selling points and competitive edge;
 - customer's continued patronage and or referrals;

2nd Floor, Oakland Centre, Australian Embassy Building, Plot 2940, Aguiyi Ironsi Street
Federal Capital Territory Maitama District, Abuja, Nigeria
TEL: + 234 - 09 - 46029147, 01 - 7306591, CEL: + 234 - 08031848907, 08057507980 FAX: 09 - 4613217
Web site: <http://www.instituteforgovernmentresearch.com>, e-mail: instituteforgovernmentresearch@gmail.com

COUNCIL

Prof. Kyari Tijani OFR Professor of Political Science/Public Administration, Chairman Prof. Ben Nwabueze CON, SAN Past Minister of Education
Chief (Mrs) Preselia Kuye FDM Past President Nigerian Bar Association Prof. Mahmood Mamman Professor of Government
Prof. Tony Travers Professor of Government Prof. David Gengen Professor of Public Leadership
Dr Blessings Chinsanga Associate Professor of Political Science & Administrative Studies
Moses Essien Country Director/CEO (Africa & Middle East)



*These are unsolicited third party opinions based on independent research. Except for claims referred to on slides 3, 4, and 5, EBM takes no responsibility for any claims. Please see Disclaimers on slides 3, 4, and 5.


Growth Strategies & Research Projects: (1)

- 1. Having established a world leadership in the area of metabolic disorder treatments through the exclusive proprietary technology of P-700, claimed to be 'World #1 technology to lower insulin resistance by all natural means', Eastwood continues to develop products on the basis of the P-700 technology. The redevelopments serve the more narrowly defined and specific needs of Alzheimer's disease, Parkinson's disease, Autism Spectrum, Cancer, Kidney diseases, and Transplant related issues.
- 2. Having already accumulated promising initial clinical results in the areas of auto-immune diseases and anti-addiction treatments, we will continue to further our efforts to develop products. Joint research projects are under way in cooperation with a few international research institutions and a few perennial Nobel Prize nominees.

Growth Strategies & Research Projects: (2)

- 3. Having 'all natural' products that can replace or substitute synthetic prescription drugs such as statins, ibuprofen, estrogen with little or no side effects, we will continue to expand the list of synthetic prescription drugs which we can replace.
- 4. Having the need for high quality organic plant sources for our herbal products, we embarked on an advanced agricultural project on a property 50km east of Seoul, Korea. The property is known to be the single largest privately owned property in Great Metropolitan Seoul area. Dr. Youngsoo Kim, CEO, owns this property.


Testimonials



We have over 5,000 video testimonials on Youtube by users and doctors with all real names and many contact information to verify.

Please see Disclaimers on slides 3, 4, and 5.

Established Retail Lines



Eleotin® Bentley

- Helps promote healthy glucose levels.
- Long-term blood glucose normalization effects.
- General health improvement.



Eleotin® Ma5

- Powerful anti-oxidation powers that are preserved superbly.
- High quality Vitamin C group ingredients.

Established Retail Lines



Eleotin® LBM

- For hyperactivity of the liver (high blood pressure).
- To cut the vicious cycle between high blood sugar and high blood pressure caused by prescription drugs.



Eleotin® Podo-Protection Socks

- Anti-Fungal & Anti-Bacterial.
- Auto Regulating Mesh Top.
- Treated Inner Toe Seam.
- Holistic & Gentle Neck Pressure.

Founder - Dr. Youngsoo Kim



- Advises Various Governments and senior management of numerous Korean firms including Hyundai, LG, and Samsung
- CEO of Mutsumi Enterprises Canada Corp. 1991-1995
- Vice President of Toshin Butsuryu (Toyota Automobile Group Japan) 1991-1995
- Assistant Professor of Finance at the University of Alberta in Edmonton 1987
- Massachusetts Institute of Technology (Ph.D. in Economics) 1987
- Section Director in Ministry of Industry and Commerce 1979
- Protocol Secretary in the Korean Presidential Palace 1978
- Section Director in Ministry of Foreign Affairs 1977

Board of Directors

Yunji Kim

President, CEO and Director

- President since April 2013, Director since October 2012
- New York State Bar admission 2012
- LL.M. in Taxation, Georgetown University Law Center, 2011

Peter Chen

CFO and Director

- Executive Director of Proterra Management Group Inc.

Dr. Terrance Owen

Director

- Director of Pacific Paredyme Energy Inc.
- CEO of CellMedX Corp.
- President and CEO of Nuva Pharmaceuticals Inc. until June 2013

Dr. Marcus Kuypers

Director

- Medical Doctor
- Physician at AB Staffing since November 2011
- Accretive Health from October 2011 to February 2013
- Doctors Home Visits from September 2001 to August 2011
- Emergency Medicine physician since November 2011



TSX-V: EBM

Yunji Kim

**Unit 1130-4871 Shell Road Richmond, B.C. Canada,
V6X 3Z6**

604.247.2100 or 1.888.669.4372

yunjikim@eastwoodcos.com

www.eleotin.ca